VRCA Verrica Pharmaceuticals Inc.

10.64
+0.06  (+1%)
Previous Close 10.58
Open 10.56
Price To Book 3.06
Market Cap 273525204
Shares 25,707,256
Volume 20,720
Short Ratio
Av. Daily Volume 62,311

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due 4Q 2019.
VP-102
Molluscum contagiosum
Phase 2 data due 2Q 2019.
VP-102
Common warts
Phase 2 trial to be initiated 1H 2019.
VP-102
Genital warts

Latest News

  1. Verrica Reports Fourth Quarter and Full Year 2018 Financial Results
  2. Verrica Pharmaceuticals Presents Positive Results from Two Phase 3 Clinical Trials of VP-102 in Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Meeting
  3. Verrica Pharmaceuticals Announces Participation in the Cowen and Company 39th Annual Healthcare Conference
  4. Verrica Announces Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Annual Meeting
  5. Verrica Appoints Neil D. DeHenes as Vice President of Distribution, Trade and Channel Strategy
  6. West Chester pharma firm to seek FDA OK for skin treatment
  7. Verrica Achieves Positive Topline Results from Two Pivotal Phase 3 Clinical Trials of VP-102 in Patients with Molluscum Contagiosum
  8. Are Insiders Buying Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock?
  9. Market Trends Toward New Normal in PlayAGS, BEST, Inc. Sponsored ADR, Verrica Pharmaceuticals, Telenav, bluebird bio, and CompX International — Emerging Consolidated Expectations, Analyst Ratings
  10. Verrica Pharmaceuticals Reports Third Quarter 2018 Financial Results
  11. Verrica Pharmaceuticals Announces Participation in the Jefferies 2018 London Healthcare Conference
  12. PhaseBio goes public in downsized $46M IPO
  13. The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx
  14. Analysts Call Verrica A Buy For Vast Molluscum Opportunity